T2C2 (Technology, Transfer, Commercialisation, Capital) has the mission to identify in Universities, Research Centres and Industry, business opportunities and turn them into real businesses. Outstanding science, high-quality entrepreneurs, intellectual property and commercial potential are the key elements and criteria that are used to select projects. T2C2 gets involved in the seed phase to support the continuation of the research and to develop the business engineering of the project. Following the seed phase, T2C2 participates with other investors in the financing of the following rounds.
| Company | Date | Round | Size | Participants |
| Cytheris | 10/06 | Series B | $30.7M | 7 |
| TransPharma Medical | 7/06 | Series C | $18M | 7 |
| BioAxone Therapeutic | 5/05 | Series B | $12.2M | 4 |
| Enobia Pharma | 1/05 | Series C | $15.6M | 4 |
